statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
read more...

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its...

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective...

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs Takeda, Astellas and Sumitomo Mitsui Banking...

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with...

U.S. FDA Approves Subcutaneous Administration of Takedas ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohns Disease

Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social...

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Tsfg LLC decreased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 12.0% during the fourth quarter, according to its most recent filing with the Securities...

Tsfg LLC Sells 3,369 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

This is a signal that TAK's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Takeda Pharmaceutical (TAK, $13.67) RSI Indicator left the oversold zone on April 01, 2024

Takeda Pharmaceutical Company Limited (NYSE:TAK  Get Free Report) dropped 2.4% during trading on Thursday . The company traded as low as $13.84 and last traded at $13.85. Approximately 333,358...

Takeda Pharmaceutical (NYSE:TAK) Trading Down 2.4%

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Watchers	3,706
52-Wk Low	$12.77
52-Wk High	$16.58

Volume	2.94M
52-Wk High	$16.58
52-Wk Low	$12.77

TAK Takeda Pharmaceutical Co Ltd (ADR)

About

Feed

News

Sentiment

Fundamentals